InsidersTradesSigma
Follow the AMGEN INC share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, AMGEN INC has published 483 public disclosures. Market capitalisation: €225.2bn. The latest transaction was reported on 13 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Grygiel Nancy A.. All data is openly available.
483
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€22m
27 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate AMGEN INC Buy (bullish), based on 29 analysts. Average price target: US$381.59.
33Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 8,707 of 29,055 companies
61.5
score / 100
Value48
Quality75
FCF yld3.5%
Earn yld3.3%
EV/EBITDA17.0x
ROE91%
Gross mgn67%
Net mgn21%
Debt/EBITDA3.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 13 August 2026
Declarations483 total
1,252 shares@ US$412.7596CommonSEC144:0001959173-26-005970
2,000 shares@ US$412.5670.0004% mcap18.2% of flowCommon StockSEC:0000318154-26-000137:0
1,252 shares@ US$162.600.0001% mcap4.5% of flowCommon StockSEC:0000318154-26-000137:1
1,252 shares@ US$416.42560.0002% mcap11.5% of flowCommon StockSEC:0000318154-26-000137:2
730 shares0Common StockSEC:0000318154-26-000135:0
2,000 shares@ US$414.210.0004% mcap27.8% of flowCommonSEC144:0001959173-26-005894
63.876 shares0Common StockSEC:0000318154-26-000131:0
103.419 shares0Common StockSEC:0000318154-26-000132:0
85.169 shares0Common StockSEC:0000318154-26-000133:0
2,069 shares@ US$162.600.0002% mcap8.2% of flowCommon StockSEC:0000318154-26-000130:0
2,069 shares@ US$402.54440.0004% mcap20.4% of flowCommon StockSEC:0000318154-26-000130:1
1,970 shares@ US$177.460.0002% mcap3.9% of flowCommon StockSEC:0000318154-26-000129:0
1,970 shares@ US$402.16010.0004% mcap8.9% of flowCommon StockSEC:0000318154-26-000129:1
1,000 shares@ US$177.310.0001% mcap2.0% of flowCommon StockSEC:0000318154-26-000129:2
1,000 shares@ US$402.16010.0002% mcap4.5% of flowCommon StockSEC:0000318154-26-000129:3
1,821 shares@ US$177.460.0002% mcap7.9% of flowCommon StockSEC:0000318154-26-000130:2
1,821 shares@ US$402.54440.0003% mcap18.0% of flowCommon StockSEC:0000318154-26-000130:3
2,670 shares@ US$447.16850.0006% mcap14.3% of flowCommonSEC144:0001974078-26-000295
2,970 shares@ US$402.000.0006% mcap14.3% of flowCommonSEC144:0001974078-26-000298
665 shares0Common StockSEC:0000318154-26-000098:0
665 shares0Common StockSEC:0000318154-26-000099:0
665 shares0Common StockSEC:0000318154-26-000100:0
665 shares0Common StockSEC:0000318154-26-000101:0
665 shares0Common StockSEC:0000318154-26-000102:0
665 shares0Common StockSEC:0000318154-26-000103:0
25 of 483 declarations
关于 AMGEN INC
Amgen Inc. 是一家在美国纳斯达克上市（股票代码 AMGN）的主要美国生物制药公司，总部位于美国加利福尼亚州千橡市。Amgen 成立于 1980 年，被广泛认为是现代生物技术领域的先驱之一，并在生物技术产业的早期建立过程中发挥了重要作用。如今，该公司是全球领先的独立生物技术公司之一，其商业模式专注于发现、开发、制造和商业化用于治疗严重慢性疾病的创新药物。（[amgen.com](https://www.amgen.com/about?utm_source=openai)) Amgen 的核心业务围绕四个治疗领域：普通医学、罕见病、炎症和肿瘤学。其产品组合包括几个对机构投资者重要的知名品牌，包括用于降低胆固醇和心血管风险的 Repatha、用于炎症性疾病的 Enbrel、用于骨骼健康的 Prolia 和 Xgeva、用于银屑病和炎症性疾病的 Otezla，以及用于严重哮喘的 Tezspire。在收购 Horizon Therapeutics 后，Amgen 加强了其在罕见病和专业免疫学资产（如 Tepezza、Krystexxa 和 Uplizna）方面的布局。（[amgen.com](https://www.amgen.com/products?utm_source=openai)) 从竞争角度来看，Amgen 结合了规模、多元化的商业基础和大量成熟产品组合以及活跃的研发管线。管理层强调公司利用生物学、人类遗传数据和技术来加速创新并提高制造效率。在地理上，Amgen 在美国拥有强大的基础，但也在多个国际地区产生销售额，使其拥有广泛的全球影响力，同时牢固地扎根于美国市场。（[amgen.com](https://www.amgen.com/about?utm_source=openai)) 近期发展具有战略重要性。在 2025 年和 2026 年，Amgen 报告了 Repatha 在心血管一级预防方面的积极 3 期数据，Tezspire 和 Uplizna 的令人鼓舞的临床更新，以及对其美国制造网络 300 million 美元的新投资。该公司还宣布在俄亥俄州扩建 900 million 美元，并在其千橡市总部建立一个超过 600 million 美元的科学创新中心。这些行动强化了 Amgen 当前的战略：扩大其工业足迹，支持供应可靠性，并继续在关键疾病领域推进高价值疗法。（[amgen.com](https://www.amgen.com/newsroom/press-releases/2025/10/landmark-phase-3-trial-vesaliuscv-meets-primary-endpoints-in-a-cardiovascular-primary-prevention-study-of-12000-patients?utm_source=openai))
